Why the study?
Does the TEG TF/K assay accurately measure activated clotting time compared to Hemochron and Hepcon devices in patients undergoing cardiopulmonary bypass?
Does the TEG TF/K assay accurately measure activated clotting time compared to Hemochron and Hepcon devices in patients undergoing cardiopulmonary bypass?
The TEG TF/K assay provides a rapid and correlated alternative to standard ACT monitoring devices during cardiopulmonary bypass, with added stability during hemodilution.
No takes yet. Share an insight, caveat, or question.
TEG TF/K may support correlated ACT monitoring in CPB; leaves open prospective validation before any practice change.
Chavez et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: